Skip NavigationSkip to Content
Return Return to Search Results

Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance

  1. Author:
    Palmer, S.
    Margot, N.
    Gilbert, H.
    Shaw, N.
    Buckheit, R.
    Miller, M.

  2. Author Address

    NCI, HIV Drug Resistance Program, Bldg 535, Room 109, Sulton St, Frederick, MD 21702 USA. So Res Inst, Infect Dis Res Dept, Frederick, MD 21701 USA. Gilead Sci Inc, Foster City, CA 94404 USA. Palmer S NCI, HIV Drug Resistance Program, Bldg 535, Room 109, Sulton St, Frederick, MD 21702 USA.
    1. Year: 2001
  2. Journal: Aids Research and Human Retroviruses
    1. 17
    2. 12
    3. Pages: 1167-1173
  4. Type of Article: Article
  5. ISSN: 0889-2229
  1. Abstract:

    New antiretroviral drugs with activity against strains of human immunodeficiency virus type 1 (HIV-1) with non-B subtypes and with resistance to current antiretroviral drugs are needed. The activity of two nucleotide analogs, tenofovir and adefovir (PMPA and PMEA, respectively), against non-B subtypes and nucleoside-resistant primary HIV-1 isolates was assessed. Tenofovir and adefovir were fully active against a panel of subtypes A, C, D, E, F, G, and group O primary HIV-1 isolates as compared with their respective activity against subtype B isolates. Moreover, the susceptibility of a panel of 10 primary HIV-1 isolates with >10-fold mean resistance to zidovudine, lamivudine, and abacavir was within 2.2-fold of wild-type tenofovir susceptibility for each isolate. An oral prodrug of tenofovir, tenofovir disoproxil fumarate (DF), is currently in phase III clinical trials for the treatment of HIV-1 infection. These in vitro susceptibility results suggest that tenofovir DF may be active in vivo against HIV-1 with nucleoside resistance as well as against HIV-1 with non-B subtypes.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1089/088922201316912772
  3. PMID: 11522186

Library Notes

  1. Fiscal Year: FY2000-2001
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel